FEMY Femasys Inc.
$1.41▲ +2.92%
Healthcare
Other
Volume 63.4K
Avg Volume (10D) 119.1K
Key Metrics & Fundamentals
Market Cap
$11.81M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.32 - 22.20
% vs 50 MA
-41.88%
% vs 200 MA
-78.25%
RSI-14
25.3
MACD Histogram
-0.0100
Beta (1Y vs SPY)
2.01
Free Cash Flow
-$3.96M
Gross Rev
$331,827
Gross Profit
$189,391
EBITDA
-$4.85M
COGS
$142,436
Operating Exp
$5.26M
Operating Income
-$5.07M
EBIT
-$5.07M
Pretax Income
-$4.47M
Net Income
-$4.47M
EPS (Diluted)
-1.33
Price & Volume History
Loading chart…
Recent News
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
GlobeNewswire · Oct 20, 2026 9:00 AM ET
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
GlobeNewswire · Oct 14, 2026 9:00 AM ET
Femasys to Showcase FemaSeed Fertility Treatment at ASRM 2026 as Commercialization Strategy Expands
InvestorsHub · Oct 8, 2026 10:38 AM ET
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
GlobeNewswire · Oct 8, 2026 9:00 AM ET
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
GlobeNewswire · Sep 15, 2026 9:00 AM ET
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
GlobeNewswire · Sep 9, 2026 9:00 AM ET
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
GlobeNewswire · Aug 26, 2026 9:00 AM ET
Femasys Secures FDA Pathway for Non-Surgical Contraceptive
Benzinga · Aug 19, 2026 1:36 PM ET
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential
Stocktwits · Aug 19, 2026 12:01 PM ET
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc
InvestorsHub · Aug 19, 2026 10:37 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See FEMY's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.